Evidence map›Paper›PMID 27074572›Full record

ArticleOncotarget2016

Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer.

Meng Zhou, Yanying Sun, Yifan Sun, Wanying Xu, Zhaoyue Zhang, Hengqiang Zhao, Zhaohua Zhong, Jie Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. LncRNAs signatures in gynecological cancers: ovarian and endometrial cancers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. LncRNAFrontiers in cell and developmental biology · 2022
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Meng ZhouCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, PR China.
Yanying SunDepartment of Microbiology, Harbin Medical University, Harbin, 150081, PR China.
Yifan SunCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, PR China.
Wanying XuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, PR China.
Zhaoyue ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, PR China.
Hengqiang ZhaoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, PR China.
Zhaohua ZhongDepartment of Microbiology, Harbin Medical University, Harbin, 150081, PR China.
Jie SunCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is growing evidence of dysregulated long non-coding RNAs (lncRNAs) serving as potential biomarkers for cancer prognosis. However, systematic efforts of searching for an expression-based lncRNA signature for prognosis prediction in ovarian cancer (OvCa) have not been made yet. Here, we performed comprehensive analysis for lncRNA expression profiles and clinical data of 544 OvCa patients from The Cancer Genome Atlas (TCGA), and identified an eight-lncRNA signature with ability to classify patients of the training cohort into high-risk group showing poor outcome and low-risk group showing significantly improved outcome, which was further validated in the validation cohort and entire TCGA cohort. Multivariate Cox regression analysis and stratified analysis demonstrated that the prognostic value of this signature was independent of other clinicopathological factors. Associating the outcome prediction with BRCA1 and/or BRCA2 mutation revealed a superior prognosis performance both in BRCA1/2-mutated and BRCA1/2 wild-type tumors. Finally, a significantly correlation was found between the lncRNA signature and the complete response rate of chemotherapy, suggesting that this eight-lncRNA signature may be a measure to predict chemotherapy response and identify platinum-resistant patients who might benefit from other more efficacious therapies. With further prospective validation, this eight-lncRNA signature may have important implications for outcome prediction and therapy decisions.

Indexed as

FemaleHumansMiddle AgedOvarian NeoplasmsPrognosisRNA, Long NoncodingTreatment OutcomeRNA, Long NoncodingBRCA1/2long non-coding RNAsoutcomeovarian cancer

Identifiers

PMID27074572
PMCPMC5078024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.